RELISTOR 12 mg/0.6 ml, solution for injection 7 bottles of 0.6 ml, CIP 3400930309971
Active ingredients: (R)-naltrexone methylbromide
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injection7 bottles of 0.6 ml, CIP 3400930309971sous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- RELISTOR 12 mg/0,6 ml, solution injectable
- Pharmaceutical form
- solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 7 flacons en verre de 0,6 mL + 7 seringues stériles avec aiguille sécurisée + 14 tampons alcoolisés
- Marketing authorisation holder
- BAUSCH HEALTH IRELAND (IRLANDE)
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 10 Oct 2025
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
60594326CIP73030997CIP133400930309971Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| BROMURE DE MÉTHYLNALTREXONEsolution | 12 mg · un flacon de 0,6 ml | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.